Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Treasury Shares (2017 - 2025)

Haemonetics has reported Treasury Shares over the past 16 years, most recently at $357631.0 for Q4 2025.

  • For Q4 2025, Treasury Shares rose 70.71% year-over-year to $357631.0; the TTM value through Dec 2025 reached $357631.0, up 70.71%, while the annual FY2025 figure was $303003.0, 18.06% down from the prior year.
  • Treasury Shares for Q4 2025 was $357631.0 at Haemonetics, down from $1.4 million in the prior quarter.
  • Over five years, Treasury Shares peaked at $1.4 million in Q3 2025 and troughed at $209494.0 in Q4 2024.
  • A 5-year average of $538545.0 and a median of $366843.0 in 2024 define the central range for Treasury Shares.
  • Biggest five-year swings in Treasury Shares: plummeted 83.25% in 2021 and later soared 157.93% in 2023.
  • Year by year, Treasury Shares stood at $248463.0 in 2021, then fell by 15.08% to $211000.0 in 2022, then soared by 372.51% to $997000.0 in 2023, then tumbled by 78.99% to $209494.0 in 2024, then soared by 70.71% to $357631.0 in 2025.
  • Business Quant data shows Treasury Shares for HAE at $357631.0 in Q4 2025, $1.4 million in Q3 2025, and $363886.0 in Q2 2025.